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Simple Summary: There is limited evidence regarding the influence of socioeconomic factors on
COVID-19 transmission, severity and outcomes in the overall population. Furthermore, there is an
urgent need to identify and explore the most important socioeconomic risk factors associated with
the COVID-19 disease among incident cancer patients, one of the most vulnerable groups of the
population. Findings from this study provide invaluable evidence needed for risk classification and
stratification among incident cancer patients, based on the information from the first pandemic wave
in the UK. We identified the clinical and socio-demographic profile of cancer patients at increased
risk of COVID-19 infection. The results from the study added knowledge on impact of the pandemic
on the most vulnerable cancer patients in the UK, and can shed light on possible treatment and
prevention strategies for COVID-19, including future vaccination prioritisation policy.
Abstract: We explored the role of socioeconomic inequalities in COVID-19 incidence among cancer
patients during the first wave of the pandemic. We conducted a case-control study within the UK
Biobank cohort linked to the COVID-19 tests results available from 16 March 2020 until 23 August
2020. The main exposure variable was socioeconomic status, assessed using the Townsend Depri-
vation Index. Among 18,917 participants with an incident malignancy in the UK Biobank cohort,
89 tested positive for COVID-19. The overall COVID-19 incidence was 4.7 cases per 1000 incident
cancer patients (95%CI 3.8–5.8). Compared with the least deprived cancer patients, those living in the
most deprived areas had an almost three times higher risk of testing positive (RR 2.6, 95%CI 1.1–5.8).
Other independent risk factors were ethnic minority background, obesity, unemployment, smoking,
and being diagnosed with a haematological cancer for less than five years. A consistent pattern of
socioeconomic inequalities in COVID-19 among incident cancer patients in the UK highlights the
need to prioritise the cancer patients living in the most deprived areas in vaccination planning. This
socio-demographic profiling of vulnerable cancer patients at increased risk of infection can inform
prevention strategies and policy improvements for the coming pandemic waves.
Keywords: coronavirus disease 2019 (COVID-19); epidemiology; pandemics; cancer; risk factors
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1. Introduction
The coronavirus disease 2019 (COVID-19), declared as a global pandemic by the
World Health Organization (WHO) on 11 March 2020 [1], has introduced a huge strain on
communities and health care systems worldwide. With the second or third pandemic wave
many countries are finding it difficult to respond to increasing health care needs of people
infected with COVID-19, especially if they are also diagnosed with other chronic diseases.
Cancer patients have a higher risk of COVID-19 infection [2], with an estimated 2-fold
increased risk of having a positive COVID-19 test, in comparison with the general popula-
tion [3]. They are also more susceptible to severe COVID-19 infection, followed by higher
morbidity and mortality, than people without cancer [2,4–6]. The main underlying reason
behind this is likely to be their immunosuppressive state, as a result of underlying malig-
nancy or anticancer treatments [7]. Therefore, it is necessary to ensure early detection of
coronavirus infection given that cancer patients have a high risk of unfavourable outcomes.
A study using the UK Biobank data found that socio-demographic factors were
relevant in determining a risk of COVID-19 infection in the general population, including
lower educational attainment and non-white ethnicity [8]. However, the influence of
socioeconomic factors on COVID-19 transmission, severity and outcomes among cancer
patients are not yet known [9]. We aimed to identify and explore the most important
socioeconomic risk factors associated with testing positive for COVID-19 among incident
cancer patients in the UK Biobank cohort.
2. Materials and Methods
2.1. Study Design and Study Participants
We developed a case-cohort study with a modified case-base sampling design con-
sisting in using the complete cohort as the control population [10]. The case-base design
involves using an extracted sample from the source population as controls, in order that
every person has the same chance of being included as a control, i.e., cases can be included
as controls. This type of sampling only works with a previously defined cohort and the
inclusion of the complete cohort as control source prevents the use of weights to upweight
sampled controls [10]. The case-base sampling provides a valid estimate of the risk ratio
(RR), without assuming that the disease is rare in the source population (Supplementary
Figure S1) [10].
Study participants were identified using the UK Biobank—a population-based prospec-
tive cohort, which recruited 502,655 volunteers aged 40–69 years, from 2006 to 2010 [11].
Each participant provided longitudinal data on sociodemographic, lifestyle, and be-
havioural factors, medical history and medications, enabling research into genetic and
lifestyle determinants of common diseases of middle and older age [11].
From all the UK Biobank participants we selected those who were diagnosed with
incident cancer regardless of the tumour site, defined as cancer cases diagnosed after
enrolment to the UK Biobank cohort in contrast to the prevalent cases diagnosed before the
enrolment. We excluded non-melanoma skin cancers and other types of non-malignant
neoplasms (ICD-10 C.44 and D.00-49). Patients who died before the first available COVID-
19 test results (i.e., 16 March 2020) were excluded to allow all participants to have the
same probability to be exposed to Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2). Dates of death were obtained from death certificates held by the NHS
Information Centre (England and Wales) and the NHS Central Register (Scotland).
Data on cancer diagnoses were obtained by UK Biobank through NHS Digital and
Public Health England (PHE) for participants in England and Wales, and NHS Central
Register and Information Services Division for participants in Scotland [12,13]. Previous
evidence linking routine registration of colorectal, lung, and breast cancer with information
from the Hospital Episode Statistics showed that the completeness of case ascertainment in
English cancer registries exceeds 98% [14]. From the selected sub-cohort of incident cancer,
we then identified our cases as all those who tested for SARS-CoV-2 with a positive result
based on data from the PHE’s Second Generation Surveillance System. It is a centralised
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microbiology database covering English clinical diagnostics laboratories that provides
national surveillance of legally notifiable infections, bacterial isolations and antimicrobial
resistance [15]. Through the individual-level linkage of these two systems, PHE provides
a regular and exhaustive feed of new COVID-19 test results for the UK Biobank partici-
pants [16]. The majority of samples tested for COVID-19 among UK Biobank participants
were from combined nose/throat swabs, while in intensive care units, lower respiratory
samples may have been taken [17]. Inpatient tests arise from specimens collected from
an acute care provider, an emergency department or an inpatient location [17]. Samples
were analysed using a reverse transcriptase polymerase chain reaction (RT-PCR) test for
SARS-CoV-2 [17].
2.2. Case-Base Constitution and Case-Control Definition
The first COVID-19 test results were released from 16 March 2020 onwards until the
31 August 2020, as part of the first wave of the COVID-19 pandemic. Therefore, the cohort
was defined as all the UK Biobank participants diagnosed with an incident cancer and
confirmed to be alive on 16 March 2020. Figure 1 shows the study flowchart, including 89
COVID-19 positive cases and 18,917 controls. Cases were defined as all incident cancer
patients tested for COVID-19 with a positive result. Controls were defined as the complete
cohort of incident cancer cases from the UK Biobank study (i.e., those patients that were
not tested for COVID-19 and those patients tested with a positive or negative result). We
assume that non-tested controls do not develop the disease.
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2.3. Sociodemographic Characteristics and Risk Factors at Baseline
The following potential COVID-19 risk factors were identified and referred as time-
fixed covariates at baseline: the Townsend Deprivation Index (TDI), age, sex, ethnicity,
employment status, smoking status, body mass index (BMI) in kg/m2, and type of cancer.
The TDI was the main risk factor, defined as an area-based measure of socio-economic
deprivation and a proxy of individuals’ socioeconomic deprivation. TDI scores were
calculated using data from the UK 2011 Census. The TDI score combines information on car
ownership, household overcrowding, owner occupation, and unemployment aggregated
for small areas of residence [18]. Higher TDI equates to a higher level of socioeconomic
deprivation. We computed the quintiles (Q) of TDI, and categorised it as Q1 for the
least deprived and Q5 for the most deprived group. Age was calculated from dates of
birth to baseline assessment. Ethnicity was self-reported and categorised as white or
white British, black or black British, Asian or Asian British, and others, including mixed
ethnicities and all other, ethnic groups. Smoking status was categorised into never, former,
and current smokers. The WHO criteria were applied to classify BMI as underweight
(<18.5 kg/m2), normal weight (18.5–24.9 kg/m2), overweight (25.0–29.9 kg/m2), and
obese (≥30.0 kg/m2) [19]. However, due to data sparsity we recategorised BMI as obese
(BMI ≥ 30.0 kg/m2) vs. non-obese (BMI < 30.0 kg/m2). Employment was categorised as
employed or self-employed (baseline category), retired, and unemployed or unpaid. Types
of cancers were classified as haematological, non-haematological, melanoma of the skin,
and other types of cancer. This categorisation was not based solely on clinical characteristics
and largely on the number of positive COVID-19 cases per each distinct cancer type (it had
to be >20 diagnosed cases). Finally, we included the duration of time following the cancer
diagnosis, classified as being diagnosed with a malignant tumour less than five or more
than five years ago.
2.4. Statistical Analyses
We described the categorical variables using counts and proportions and the continu-
ous variables using medians and interquartile ranges by case control status. Afterwards, we
estimated the risk of testing COVID-19 positive by all the sociodemographic, employment
status, BMI and cancer type and time duration after the cancer diagnosis. Due to the use
of the complete cohort as main control source for analysis we did not include weights
to correct for the sampling design. However, the variance estimates were adjusted (i.e.,
robust standard errors) to account for the inclusion of the cases as controls in the overall
cohort [20]. Therefore, we computed univariate risk ratios and their respective robust 95%
confidence intervals (CIs) [20,21].
To assess the association between socio-economic deprivation and the risk of testing
positive for COVID-19, we fitted different multivariate regression models, including one
variable at a time, to control for confounding (i.e., Models 1–8). The final model was
adjusted for age, sex, ethnicity, employment, marital and smoking status, cancer types
and years of cancer diagnosis. From each model, we derived the risk ratios (RRs) and
95% CIs using a generalised linear model with the family Poisson and link log and robust
error variance estimation [20,21]. From the final adjusted model (Model 8) we derived the
adjusted marginal probabilities of testing COVID-19 positive by levels of deprivation (Q5
vs. Q1) stratified by gender and across the levels of BMI.
Given the low proportion of missing data, we first performed a complete-case anal-
ysis, adopting the missing completely-at-random assumption. However, to assess the
consistency of our results for the socioeconomic deprivation, we developed a multiple
imputation by chained equations. We imputed 50 datasets for the variable’s ethnicity,
smoking, employment, and marital status. The multiple imputation results were combined
using Rubin’s rules [22]. These estimates were presented in Model 9.
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Furthermore, in sensitivity analyses we explored different modelling specifications
and the assumption that non-tested controls do not develop the COVID-19 (supplemen-
tary Technical notes 1). We used Stata v.16 (Stata Corp, College Station, TX, USA) for
statistical analysis.
2.5. Ethics Approval and Consent to Participate
This UK Biobank study was approved by the North West Multi-Centre Research Ethics
Committee (application number 48860); all participants provided written informed consent
for data collection, data analysis, and record linkage.
3. Results
The characteristics of the test positive (cases) (N = 89) and the entire cohort (controls)
(N = 18,917) are detailed in Table 1. The overall incidence in our study was 4.7 cases per
1000 incident cancer patients (95% CI: 3.8–5.8). Overall, 4090 (21.6%) participants were
in the most deprived category, and 3604 (19.1%) in the most affluent group. The median
age of the test positive group was 74 years (interquartile range [IQR], 68–78 years) and
52.8% were male. The majority of them were white (91.0%), while 4.5% were black. 74
of 89 test-positive patients (83.1%) had non-haematological cancer, of which malignant
neoplasm of the breast, prostate, colorectal, and urogenital were the most common primary
tumour sites (Supplementary Table S1). We did not find statistically significant differences
between the cases and controls regarding the distributions of cancer types, or the duration
of time following the cancer diagnosis.
Table 1. Case-Cohort Control Study Socioeconomic Characteristics, Smoking Status BMI, and Cancer
Type Among UK Biobank Incident Cancer Patients at Baseline on 16 March 2020 (N = 18,917, 89 cases).
Characteristics Tested Positive(Cases) N (%)
Entire Cohort
(Controls) N (%) p-Values
Age, years 0.177 *
Median (interquartile range) 74 (68–78) 73 (67–77)
Quintiles of Deprivation 0.013
1st quintile (most affluent) 8 (9.0) 3604 (19.1)
2nd quintile 16 (18.0) 3682 (19.5)
3rd quintile 18 (20.2) 3659 (19.3)
4th quintile 15 (16.9) 3863 (20.4)
5th quintile (most deprived) 31 (34.8) 4090 (21.6)
Sex 0.518
Female 42 (47.2) 9577 50.6)
Male 47 (52.8) 9340 (49.4)
Ethnicity 0.031
White 81 (91.0) 18,075 (95.6)
Asian 2 (2.3) 284 (1.5)
Black 4 (4.5) 234 (1.2)
Others 2 (2.3) 220 (1.2)
Marital status 0.726
With a partner 68 (76.4) 14,048 (74.3)
Without a partner 5 (5.6) 1215 (6.4)
Employment 0.031
Employed or self-employed 33 (37.1) 9240 (48.8)
Retired 42 (47.2) 8197 (43.3)
Unemployed/unpaid 11 (12.4) 1283 (6.8)
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Table 1. Cont.
Characteristics Tested Positive(Cases) N (%)
Entire Cohort
(Controls) N (%) p-Values
Smoking status 0.022
Current smoker 12 (13.5) 1767 (9.3)
Ex-smoker 43 (48.3) 7251 (38.3)
Non-smoker 33 (37.1) 9772 (51.7)
BMI (kg/m2) 0.001 *
Median (interquartile range) 28.6 (26.1–31.9) 27.0 (24.5–30.1)
Categorical BMI 0.026
<18.5 0 (0.0) 64 (0.3)
18.5–24.9 16 (18.0) 5557 (29.4)
25.0–29.9 38 (42.7) 8412 (44.5)
≥30 33 (37.1) 4795 (25.4)
Malignancy types 0.069
Haematological cancers 12 (0.8) 1518 (99.2)
Non-haematological cancers 74 (0.5) 15,975 (99.5)
Skin melanoma and others 3 (0.2) 1424 (99.8)
Years of cancer diagnosis 0.052
Within 5 years of diagnosis 21 (23.6) 3027 (16.0)
Beyond 5 years of diagnosis 68 (76.4) 15,883 (84.0)
Total numbers 89 (0.5) 18,917 (100.0)
Missing values
Quintiles of deprivation 1 (1.1) 19 (0.1)
Ethnicity 0 (0.0) 104 (0.6)
Marital status 16 (18.0) 3654 (19.3)
Employment 3 (3.4) 197 (1.0)
Smoking 1 (1.1) 127 (0.7)
BMI 2 (2.2) 89 (0.5)
Years of cancer diagnosis 0 (0.0) 7 (0.0)
* Kruskal-Wallis rank test. BMI: Body Mass Index in kg/m2.
In univariate analysis, black patients had nearly four times higher risk of testing
COVID-19 positive than whites (i.e., crude risk ratio [cRR] of 3.77 and 95% confidence
interval [CI]: 1.39–10.20). Individuals living in more deprived areas had approximately
4 times higher risk of testing positive for COVID-19 than those individuals from the
least deprived areas (i.e., the least deprived quintile of the Townsend index (Q5) vs. the
most affluent quintile (Q1) was 3.40; 95% CI: 1.56–7.38) (Table 2). Furthermore, being
unemployed or unpaid, current smoker or ex-smoker, having high BMI, or being diagnosed
with haematological cancers were strongly associated with an increased risk of testing
positive for COVID-19.
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Table 2. Case-Cohort Control Study Unadjusted Risk Ratios of Testing COVID-19 Positive among
UK Biobank Incident Cancer Patients by Deprivation, Age, Sex, Ethnicity, Employment Status, BMI
and Cancer Types and Duration (N = 18,917 and 89 cases).
Characteristics Crude RR (95% CI) p-Value
Age
per ten-year increase 1.17 (0.83–1.64) 0.353
Sex
Male vs. Female 1.15 (0.76–1.74) 0.518
Ethnicity
Asian vs. White 1.57 (0.39–6.34) 0.529
Black vs. White 3.77 (1.39–10.20) 0.009
Others vs. White 2.02 (0.50–8.16) 0.324
Marital status
With a partner vs. Without partner 1.18 (0.47–2.91) 0.727
Quintiles of Townsend deprivation index
2nd quintile vs. 1st quintile 1.95 (0.84–4.56) 0.121
3rd quintile vs. 1st quintile 2.21 (0.96–5.08) 0.062
4th quintile vs. 1st quintile 1.75 (0.74–4.11) 0.202
5th quintile vs. 1st quintile 3.40 (1.56–7.38) 0.002
Employment status
Retired vs. employed 1.43 (0.91–2.26) 0.122
Unemployed/unpaid vs. employed 2.39 (1.21–4.71) 0.012
Smoking status
Current smoker vs. non-smoker 2.00 (1.04–3.87) 0.039
Ex-smoker vs. non-smoker 1.75 (1.11–2.75) 0.015
BMI
(per five kg/m2 increase) 1.30 (1.08–1.56) 0.006
Categorical BMI in kg/m2
Obesity (≥30) vs. Normal/overweight (<30) 1.78 (1.16–2.75) 0.009
Malignancy types
Hematological cancer vs. Skin melanoma/others 3.73 (1.05–13.19) 0.041
Non-hematological cancer vs. Skin melanoma/others 2.19 (0.69–6.95) 0.182
Years of cancer diagnosis
Within 5 years vs. Beyond 5 years of diagnosis 1.62 (0.99–2.63) 0.054
Abbreviations: BMI, Body Mass Index; RR, Risk Ratio.
In multivariate analysis, we controlled for confounding adding successively one
variable at a time in the multivariate regression model (Table 3). Our final complete-
case model (Model 8) found a consistent and independent association between being
socioeconomically deprived (TDI Q5) and testing positive for COVID-19, with an adjusted
risk ratio (aRR) of 2.52 (95% CI 1.00–6.33). Black patients had almost 6 times higher risk of
testing positive for COVID-19 in comparison with white patients (i.e., aRR 5.79; 95% CI
1.88–17.85). Furthermore, this risk among unemployed was two times higher than among
employed patients (aRR 2.35; 95% CI 1.06–5.20) and increased by 41% for each 5 kg/m2
increase in BMI (aRR 1.41; 95% CI 1.20–1.67) (Table 3: Model 8).
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Table 3. Case-Cohort Control Study Adjusted Risk Ratios of Testing COVID-19 Positive among UK Biobank Incident Cancer Patients by Deprivation, Age, Sex, Ethnicity, Employment
Status, BMI and Cancer Type (N = 18,917).


















2nd vs. 1st 1.96 (0.84–4.58) 1.96 (0.84–4.58) 1.84 (0.78–4.34) 1.81 (0.77–4.28) 1.79 (0.76–4.23) 1.80 (0.76–4.25) 1.79 (0.76–4.24) 2.09 (0.85–5.13) 1.90 (0.82–4.46)
3rd vs. 1st 2.22 (0.97–5.11) 2.21 (0.96–5.09) 2.21 (0.96–5.08) 2.18 (0.95–5.01) 2.01 (0.86–4.68) 2.02 (0.87–4.69) 2.00 (0.86–4.65) 2.02 (0.81–5.04) 1.98 (0.85–4.61)
4th vs. 1st 1.78 (0.75–4.19) 1.74 (0.74–4.07) 1.74 (0.74–4.07) 1.56 (0.65–3.72) 1.49 (0.63–3.54) 1.49 (0.63–3.53) 1.49 (0.63–3.54) 1.78 (0.72–4.42) 1.60 (0.68–3.76)
5th vs. 1st 3.46 (1.59–7.53) 3.20 (1.45–7.06) 2.86 (1.27–6.41) 2.69 (1.21–6.00) 2.41 (1.05–5.55) 2.38 (1.04–5.48) 2.37 (1.03–5.44) 2.52 (1.00–6.33) 2.57 (1.13–5.85)
Sex
male vs. female 1.13 (0.74–1.74) 1.11 (0.72–1.72) 1.16 (0.74–1.83) 1.12 (0.72–1.75) 1.16 (0.73–1.85) 1.16 (0.73–1.85) 1.16 (0.73–1.83) 1.20 (0.71–2.02) 1.08 (0.69–1.70)
Age
per ten-year increase 1.17 (0.83–1.73) 1.21 (0.86–1.70) 1.15 (0.73–1.81) 1.12 (0.70–1.80) 1.10 (0.68–1.78) 1.08 (0.67–1.76) 1.10 (0.68–1.78) 1.10 (0.66–1.84) 1.12 (0.70–1.80)
Ethnicity
Asian vs. White 1.49 (0.36–6.04) 0.74 (0.10–5.41) 0.91 (0.12–6.61) 0.97 (0.13–7.39) 0.93 (0.12–7.09) 0.94 (0.13–6.89) 1.16 (0.14–9.31) 1.64 (0.39–6.89)
Black vs. White 2.92 (0.99–8.67) 2.97 (1.00–8.85) 3.43 (1.21–9.77) 3.52 (1.19–10.45) 3.39 (1.14–10.07) 3.41 (1.15–10.11) 5.79 (1.88–17.85) 3.44 (1.13–10.46)
Others vs. White 1.86 (0.47–7.30) 1.80 (0.46–7.05) 1.89 (0.46–7.82) 2.00 (0.51–7.83) 1.94 (0.50–7.58) 1.91 (0.49–7.46) 2.83 (0.73–10.91) 1.80 (0.46–7.06)
Employment status
Retired vs. employed 1.29 (0.74–2.24) 1.32 (0.76–2.31) 1.28 (0.72–2.26) 1.28 (0.72–2.27) 1.28 (0.72–2.26) 1.39 (0.79–2.46) 1.22 (0.69–2.14)
Unemployed/unpaid vs. employed 2.09 (1.03–4.24) 2.11 (1.04–4.29) 2.01 (0.99–4.09) 2.00 (0.98–4.07) 1.99 (0.98–4.04) 2.35 (1.06–5.20) 2.07 (1.02–4.20)
Smoking status
Current smoker vs. non-smoker 1.44 (0.71–2.96) 1.51 (0.74–3.06) 1.49 (0.73–3.02) 1.49 (0.73–3.04) 1.30 (0.54–3.16) 1.77 (0.91–3.44)
Ex-smoker vs. non-smoker 1.69 (1.07–2.68) 1.57 (0.99–2.50) 1.56 (0.98–2.49) 1.56 (0.98–2.49) 1.53 (0.93–2.52) 1.56 (0.98–2.47)
BMI
Per 5 kg/m2 increase 1.28 (1.08–1.52) 1.29 (1.09–1.52) 1.28 (1.08–1.51) 1.41 (1.20–1.67) 1.27 (1.08–1.50)
Malignancy type
Haematological vs. skin melanoma and
** others 4.21 (0.92–19.33) 4.18 (0.91–19.18) 3.94 (0.84–18.38) 4.30 (0.94–19.70)
Non-haematological vs. skin melanoma
and ** others 2.74 (0.67–11.22) 2.74 (0.67–11.19) 2.31 (0.56–9.53) 2.80 (0.69–11.46)
Years of cancer diagnosis
Within 5 years vs. beyond 5 years
of diagnosis 1.55 (0.93–2.58) 1.44 (0.81–2.56) 1.67 (1.02–2.73)
Marital status
With a partner vs. without a partner 2.36 (0.66–8.35) 1.36 (0.52–3.57)
Abbreviations: aRR, adjusted risk ratio; BMI, body mass index; M1: adjusted for Townsend Deprivation Index, age, and sex; M2: M1 + Ethnicity; M3: M2 + Employment status; M4: M3 + Smoking status; M5:
M4 + BMI in kg/m2; M6: M5 + Malignancy type; M7: M6 + Years of cancer diagnosis; M8: M7 + Marital status; M9: Multiple imputation. * Model 8 is the final model. ** others: all other cancers excluding
non-melanoma skin cancers and other types of non-malignant neoplasms (ICD-10 C.44 and D.00-49).
Cancers 2021, 13, 1514 9 of 14
Based on the risks estimated from Model 8, we predicted the probabilities of testing
positive for COVID-19 for the most and least deprived individuals of the studied cohort,
given their respective observed distribution of the covariables included in the model. The
probabilities are stratified by sex (Figure 2) and BMI (Figure 3). Overall, we found a clear
deprivation gap, but the figures show no evidence of significant differences in COVID-19
positive tests between men and women. Differences between the two sexes were, however,
more pronounced among the most deprived group (Figure 2). Figure 3 shows a constant
deprivation gap in the probability of testing positive between the most and least deprived
cancer patients that widens with increasing levels of BMI and even strengthens among
obese cancer patients (i.e., BMI > 30.0 kg/m2). Results of the sensitivity analysis are
detailed in supplementary Technical notes 1 and Table S2. The effect estimates for being
most deprived were consistent in sensitivity analyses based on controls consisting of either
test negative or non-tested participants.
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4. Discussion
We found a consistent and independent association between socioeconomic depri-
vation and the risk of COVID-19 positive test results among incident cancer cases in the
UK Biobank study. Participants with an increased risk of testing positive for COVID-19
during the first wave of the pandemic in the UK had a black ethnic background, lived in
the most socioeconomically deprived areas, were obese, unemployed and diagnosed with
a haemopoietic cancer, for less than five years.
Our results are consistent with the stark ethnic inequalities evident in the recent
estimates of COVID-19 mortality during the first wave of the pandemic by ethnic groups
in England and Wales [23,24]. As published by the Office for National Statistics in the
UK, the rate of COVID-19 related deaths was 2.7 times higher for black African men then
for white men [23]. Thus, we argue that an increased risk of testing COVID-19 positive
among black ethnic groups may partially explain the increased mortality risk observed
in the UK. Furthermore, the incidence rate in our study (i.e., 4.7 cases per 1000 people)
was consistent with the reported figure for the whole UK. The total population in the UK
was 66,796,800 (mid-year estimate in 2019 according to the Office for National Statistics
of the UK) and the total number of cases as of the 1st August 2020 was 303,942 [25,26],
corresponding to an incidence rate was 4.6 per 1000 people. COVID-19 incidence was
similar in both populations (general and cancer patients) while external contacts were
lower for cancer patients. The is likely to be due to cancer patients’ caution (“shielding”),
dramatically reduced delivery of non-COVID-19-related care by the NHS during the first
wave of the pandemic, the fear of healthcare interactions during the COVID-19 pandemic or
misunderstanding that healthcare services were not available to all but limited to COVID-19
patients only [27,28].
Health surveys in the UK have shown that unemployment, smoking, and obesity
are most common among ethnic minorities [24,29]. Stress associated with an unhealthy
lifestyle or lack of financial security may result in a pro-inflammatory condition, increasing
susceptibility to infections [30,31]. In a study by Shree et al. [32,33], long-term cancer
survivors have experienced increased incidence of many infections, have particularly viral
and fungal infections among diffuse large B-cell lymphoma and Hodgkin lymphoma sur-
vivors. The immune dysfunction can be related to long-lasting changes in the functioning
of the immune system due to cancer diagnosis and past treatments. The increased risk for
COVID-19 infection found among the most socioeconomically deprived incident cancer
patients could point to a potential role for proinflammatory and metabolic condition in
combination with cancer-related immune dysfunction leading to increased vulnerability
to infections.
Socioeconomic status is a multifaceted construct, and therefore, not only determined
by the individuals’ income. We argue that the disparities in testing positive for COVID-19
we found during the first wave of the pandemic reflect the health, environmental, and
occupational effects of socioeconomic inequalities. These disparities may be partially
explained by the higher likelihood of ethnic minorities to work in lower paid occupations
that demand proximity to other people (e.g., delivery staff, security or cleaning services,
social or health care assistants) or work colleagues (e.g., construction industry), offering
less flexibility to work from home, or living in cramped residential settings that preclude
social distancing (i.e., several generations living together) [34–39].
Our study highlights the necessity of reporting data on socioeconomic determinants of
COVID-19 disease, especially information about ethnicity to identify high-risk populations
and develop equitable public health prevention measures, guidelines, and interventions. A
multi-sectoral approach would reduce disparities by considering the vulnerabilities at a
social, educational, economic, and provision-of-care levels. Furthermore, findings from our
study may help to prioritise future COVID-19 preventive strategies, especially vaccination
priority, among cancer patients undergoing active treatments However, more research is
needed regarding comparative risk assessment for COVID-19 infection among cancer and
the overall population and the cancer specific survival after COVID-19 infection.
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UK Biobank has been meticulously tracking the health status of its participants for
over a decade. Many participants are now in the age range likely to be most vulnerable
to COVID-19 infection as well as at higher risk of being diagnosed with cancer. Using the
case-cohort approach we derived risk estimates for positive COVID-19 test results based
on a valid and consistent methodological approach [40,41]. However, there are possible
issues around generalisability of the UK Biobank data, which was previously criticised [42].
Although the UK Biobank might not be completely representative of the UK population
and therefore the results may not be entirely generalizable, or suitable for identifying
disease prevalence or incidence rates, its large size and heterogeneity of exposure measures
provide valid scientific inferences of associations between exposures and health conditions
that are generalizable to other populations [42]. Furthermore, we were unable to perform
cancer specific analysis due to small number of confirmed COVID-19 cases by cancer
sites. However, we were able to classify malignancies in clinically relevant categories, i.e.,
haematological cancers, non-haematological cancers, skin melanoma, and other types of
cancers. The classification was not based on clinical characteristics; rather it was based
on the number of positive COVID-19 cases per each distinct cancer type (it had to be >20
diagnosed cases).Finally, we assume that controls that were not tested for COVID-19 do
not develop the disease which may have induced a selection bias because some of the
cancer patients might be asymptomatic [43]. We argue that given their cancer status the
majority of control patients developing symptoms compatible with COVID-19 they would
have been tested, also we have performed sensitivity analyses demonstrating consistency
of results even if non-tested patients were excluded from analysis. Furthermore, in our
sensitivity analysis, the results were consistent when restricting the controls to only non-
tested patients excluding those testing negative on COVID-19 (comparing test positive
versus non-tested patients).
5. Conclusions
To the best of our knowledge, this study is the first to highlight a consistent and
independent association between socioeconomic deprivation and the risk of COVID-19
infection among incident cancer patients in the UK. Policy and practice improvements
based on high ethical principles are needed to address the broad disparity and risk stratifi-
cation among the most vulnerable cancer patients at risk for COVID-19. It is essential to
develop effective preventive measures targeting cancer patients at highest risk, such as an
urgent vaccination of the underprivileged cancer patients, to confront the future potential
pandemic waves.
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COVID-19, excluding those with a negative result. Technical notes 1: Sensitivity analyses. Figure S1:
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